{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:04:05Z","timestamp":1775858645759,"version":"3.50.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-lineage acute lymphoblastic leukemia (B-ALL). Chimeric antigen receptor T-cell therapy makes use of T cells that have been modified to target a cancer-specific cell surface antigen. There is currently 1 Food and Drug Administration\u2013approved CD19-directed CAR T-cell therapy for relapsed\/refractory B-ALL with numerous other CAR T-cell products under clinical investigation. This review covers the development of CAR T cells for B-ALL, citing the remarkable efficacy of inducing remissions in a very high-risk population of patients. However, following the first round of CAR T-cell trials targeting CD19 in B-ALL, it has been found that approximately 50% of patients who initially respond will ultimately recur. Current efforts in the field are focusing on the identification of targets beyond CD19 as well as advancing strategies to promote more durable remissions as work is ongoing to move this therapy upfront.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000375","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:13:32Z","timestamp":1558754012000},"page":"191-198","source":"Crossref","is-referenced-by-count":17,"title":["Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"25","author":[{"given":"Francesco","family":"Ceppi","sequence":"first","affiliation":[{"name":"Pediatric Hematology-Oncology Research Laboratory & Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, University Hospital of Lausanne, Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11912-008-0070-3","article-title":"Relapsed acute lymphoblastic leukemia: current status and future opportunities","volume":"10","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.01.024","article-title":"Monoclonal antibody therapy for B-cell malignancies","volume":"33","year":"2006","journal-title":"Semin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2013.828354","article-title":"Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond","volume":"55","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","year":"2006","journal-title":"Cancer Res"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14653240701656079","article-title":"Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning","volume":"9","year":"2007","journal-title":"Cytotherapy"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/hum.2009.142","article-title":"Fifteen years of gene therapy based on chimeric antigen receptors: \u201care we nearly there yet?\u201d","volume":"20","year":"2009","journal-title":"Hum Gene Ther"},{"key":"bib16-20230924","first-page":"303ra139","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","article-title":"CAR-T cell therapies from the transfusion medicine perspective","volume":"30","year":"2016","journal-title":"Transfus Med Rev"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","year":"2018","journal-title":"Transfusion"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood.V130.Suppl_1.809.809","article-title":"CD4\/CD8 T-cell selection enhances CD22 CAR-T cell transduction and in-vivo CAR-T expansion: updated results on phase I anti-CD22 CAR dose expansion cohort","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor\u2013modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","year":"2008","journal-title":"J Clin Invest"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)\u2013modified T cells in children with relapsed\/refractory ALL","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2018-99-111531","article-title":"Updated phase 1 results of Zuma-3: Kte-C19, an anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)\u2013modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL)","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2018-99-111856","article-title":"Sequential CD19\u2013 and CD22\u2013CART cell therapies for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood-2018-99-118616","article-title":"Simultaneous targeting of CD19 and CD22: phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy, in pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL): Amelia study","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2018-99-112285","article-title":"Novel CD19t T-antigen presenting cells designed to re-activate and expand CD19 CAR T cells in vivo: early demonstration of feasibility and safety","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential Anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib44-20230924","first-page":"320ra3","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","year":"2016","journal-title":"Sci Transl Med"},{"key":"bib45-20230924","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","year":"2017","journal-title":"Sci Transl Med"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib47-20230924","article-title":"ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"bib50-20230924","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T cell therapy","year":"2017","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2018-99-110164","article-title":"Minimal change in CAR T cell manufacturing can impact in expansion and side effect of the CAR T cell therapy","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib59-20230924","first-page":"95ra73","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","year":"2011","journal-title":"Sci Transl Med"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","article-title":"Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","year":"2017","journal-title":"Leukemia"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:16:25Z","timestamp":1695532585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000375","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}